Skip to main content

Study Reveals MASLD, MetALD Responsible for One-Third of ICU Cirrhosis Cases

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 6, 2024.

By Lori Solomon HealthDay Reporter

TUESDAY, Aug. 6, 2024 -- Metabolic dysfunction-associated steatotic liver disease (MASLD)-related and metabolic and alcohol-related liver disease (MetALD)-related cirrhosis is responsible for one-third of cirrhosis cases seen in the intensive care unit (ICU), according to a study published online July 22 in Alimentary Pharmacology and Therapeutics.

Philippe Sultanik, M.D., Ph.D., from Sorbonne Université in Paris, and colleagues assessed the prevalence of MASLD-related cirrhosis in the ICU (January 2019 to September 2021) among 315 patients (39 with MASLD, 160 with alcohol-related liver disease [ALD], and 116 with MetALD cirrhosis).

The researchers found that patients in the MASLD group were significantly older (65 years versus 57 and 59 years, respectively) and had lower Child-Pugh (8 versus 11 and 10, respectively) and Model for End-Stage Liver Disease scores (17 versus 22 and 21, respectively). There were no differences in one-year transplant-free survival between the groups (53 percent versus 54 and 54 percent, respectively). All groups had cardiovascular mortality of less than 5 percent. The MASLD group had a significantly higher one-year probability of developing hepatic encephalopathy (73 percent versus 27 and 21 percent, respectively).

"MASLD or MetALD was responsible for one-third of the causes of cirrhosis in the ICU," the authors write. "MASLD-related cirrhosis is as severe as ALD-related cirrhosis. Liver transplantation should be rapidly discussed."

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

DDW: Certain Proteins Predict Metabolic Dysfunction-Associated Steatotic Liver Disease

FRIDAY, April 25, 2025 -- Five proteins are significant predictors of metabolic dysfunction-associated steatotic liver disease (MASLD), according to a study presented at the 2025...

Metabolic Syndrome Linked to Increased Risk for Young-Onset Dementia

THURSDAY, April 24, 2025 -- Metabolic syndrome (MetS) and its individual components are associated with an increased risk for young-onset dementia (YOD), according to a study...

Metabolic Surgery May Be Beneficial in MASH-Related Cirrhosis, Obesity

MONDAY, Feb. 3, 2025 -- For patients with compensated metabolic dysfunction-associated steatohepatitis (MASH)-related cirrhosis and obesity, metabolic surgery is associated with a...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.